Drug Profile
Research programme: glycogen synthase kinase-3 beta inhibitors - Angelini
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Angelini Group
- Class
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Neurodegenerative disorders; Psychiatric disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psychiatric-disorders in Italy